As a Vice President in the Healthcare vertical, Nathan builds relationships with management, develops investment theses and manages internal and external due diligence. He works across a variety of Identified Sector Opportunities (ISOs), such as Consumer Healthcare, Healthcare Information Technology (HCIT) and Pharma Services.

Before joining the THL team, Nathan worked as a Vice President at Norwest where he invested in Healthcare Services and Healthcare Technology companies. Previously, he worked at J.P. Morgan as an Investment Banking Analyst in the Healthcare Group. In his free time, Nathan enjoys reading non-fiction, traveling, weightlifting and anything featuring Conan O’Brien.

Verticals
Healthcare (HC)
Verticals
Healthcare (HC)

Related content

From One to Twenty: How CSafe Became a Leader in the Pharma Cold Chain
Insights
From One to Twenty: How CSafe Became a Leader in the Pharma Cold Chain 

In the world of pharmaceutical logistics, maintaining the precise temperature of biologically based therapies like the Covid vaccine is mission critical. Even minor temperature fluctuations can compromise the efficacy of life-saving drugs. CSafe, a leading provider of cold chain shipping solutions, ensures that pharmaceutical products reach their destination without deviation from required temperature set points. Its

Healthcare (HC)
Why We Invested in Red Nucleus: A Pharma Commercialization Leader
Insights
Why We Invested in Red Nucleus: A Pharma Commercialization Leader 

Key Takeaways: In October 2024, THL announced its investment in Red Nucleus, a leading provider of pharma commercialization services. Pharma commercialization businesses are more critical than ever, as notable sector tailwinds — including the rise of complex therapies and a growing need for outsourced services — require specialized expertise to navigate market access, regulatory hurdles, and stakeholder

Healthcare (HC)

Want to learn more?